| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f8c0982b0f02b1ed6d20a315370a3a3a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2e3c952ff24523fe80356c5944f5313b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b82f0f38f6f84aaba2737cb84b1ff646
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_54d9e1c6d2367d6ec841a92acf08a06c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2035-124 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0692
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0647 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-078
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-071 |
| filingDate |
2006-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7980b9c02798f43dc0205212789cb65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9bb870ffadff436372bfb8e8f6769a45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_656992967fc38a03186ea5cc5d0a5fc0 |
| publicationDate |
2006-10-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2006104609-A2 |
| titleOfInvention |
Isolated myeloid-like bone marrow cell populations and methods of treatment therewith |
| abstract |
The present invention provides an isolated myeloid-like bone marrow cell population comprising a majority of cells that are lineage negative, and which express both CD44 antigen and CD11b antigen. These cells have beneficial vasculotrophic and neurotrophic activity when intraocularly administered to the eye of a mammal, particularly a mammal suffering from an ocular degenerative disease. The myeloid-like bone marrow cells are isolated by treating bone marrow cells with an antibody against CD44 (hyaluronic acid receptor), against CD11b, or against both and using flow cytometry to positively select CD44 and/or CD11b expressing cells therefrom. The isolated myeloid-like bone marrow cells of the invention can be transfected with a gene encoding a therapeutically useful protein, for delivering the gene to the retina. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8420619-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2247258-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012005763-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008063564-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2086333-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2473686-C2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8242093-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2086333-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010509916-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2007322084-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2247258-A1 |
| priorityDate |
2005-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |